Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

215.51
-1.2600-0.58%
Post-market: 215.510.00000.00%18:46 EST
Volume:995.06K
Turnover:213.71M
Market Cap:10.61B
PE:-140.86
High:216.97
Open:213.90
Low:208.67
Close:216.77
52wk High:217.89
52wk Low:91.86
Shares:49.22M
Float Shares:48.62M
Volume Ratio:1.66
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5300
EPS(LYR):0.2004
ROE:-2.19%
ROA:4.33%
PB:3.11
PE(LYR):1,075.36

Loading ...

Charles River Laboratories: Overdone CEO-Transition Selloff Creates Attractive Entry Point Amid Improving Fundamentals

TIPRANKS
·
Yesterday

BRIEF-Charles River Laboratories Announces Planned Retirement Of James C. Foster

Reuters
·
Yesterday

Charles River Laboratories Names Birgit Girshick as Next CEO

Reuters
·
Yesterday

Charles River Laboratories International Inc: Birgit Girshick Unanimously Appointed Next Chief Executive Officer, Also Effective in May 2026

THOMSON REUTERS
·
Yesterday

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

THOMSON REUTERS
·
Yesterday

FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug

Benzinga_recent_news
·
Jan 06

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 06

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 03

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jan 01

BUZZ-Life sciences and contract research stocks navigate turbulence in 2025

Reuters
·
Dec 31, 2025

What Caused Multi Ways Holdings (MWG) To Soar Nearly 49% In After-Hours Trading?

Benzinga
·
Dec 24, 2025

Press Release: Multi Ways Holdings Reports 88% Revenue Growth in First Half 2025, Provides Corporate Updates

Dow Jones
·
Dec 24, 2025

Charles River Laboratories International Inc. Stock Climbs 3.0%, Outperforms Peers

Dow Jones
·
Dec 23, 2025

Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Benzinga_recent_news
·
Dec 23, 2025

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

GlobeNewswire
·
Dec 22, 2025

Charles River Laboratories International Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Dec 19, 2025

Charles River Laboratories International Inc : Mizuho Raises Target Price to $200 From $174

THOMSON REUTERS
·
Dec 18, 2025

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

Reuters
·
Dec 18, 2025

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Dec 16, 2025

Charles River Labs Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 16, 2025